OUR TEAM

Our leadership team possesses rich and diverse industry knowledge, a passion for science and a shared commitment to help transform lives.

Made up of our founding scientists, industry experts, Nobel Laureates and members of the National Academy of Sciences, we consistently push the boundaries of scientific excellence and discovery.

  • Leonard S. Schleifer

    Leonard S. Schleifer, MD, PhD

  • George D. Yancopoulos

    George D. Yancopoulos, MD, PhD

  • Founder, President and Chief Executive Officer

    Leonard S. Schleifer, MD, PhD, founded the company in 1988 while serving as an Assistant Professor of Neurology at Weill Cornell Medical College. Leveraging a lifelong passion for science and an entrepreneurial spirit, he has served as a Director and its President and Chief Executive Officer since its inception and acted as Chairman of the Board from 1990 through 1994. Dr. Schleifer received his MD and PhD in Pharmacology from the University of Virginia, and he is a licensed physician certified in neurology by the American Board of Psychiatry and Neurology.

  • President and Chief Scientific Officer

    George D. Yancopoulos, MD, PhD, is Regeneron’s President and Chief Scientific Officer. He has led Regeneron alongside Len Schleifer, MD, PhD, since 1989. George has been driven by science his entire life. He began his education at the Bronx High School of Science, received his MD and PhD from Columbia University and went on to become the 11th most highly cited scientist in the world in the 1990s. In 2004, he was elected to be a member of the National Academy of Sciences. Dr. Yancopoulos, together with key members of his team, is a principal inventor and developer of Regeneron's six FDA-approved drugs, as well as its foundational technologies, including the Trap technology, VelociGene® and VelocImmune®.

  • Ned Braunstein

    Ned Braunstein, MD

  • Thomas Daly

    Thomas Daly, PhD

  • James P. Fandl

    James P. Fandl, PhD

  • Senior Vice President, Regulatory Affairs & Pharmacovigilance

    Ned Braunstein, MD, joined Regeneron in 2009, and serves as Senior Vice President, Regulatory Affairs. Prior to Regeneron, he worked at Columbia University College of Physicians and Surgeons for 13 years as Assistant and then Associate Professor of Medicine and at Merck & Co., Inc, for nine years in positions of increasing responsibility in Clinical Research, Regulatory Affairs and Global Human Health. Dr. Braunstein received his BS in Medicine from Northwestern University in Evanston, Ill., and his MD from Northwestern University in Chicago.

  • Senior Vice President, Preclinical Development & Protein Chemistry

    Thomas Daly, PhD, joined Regeneron in 1996. He is Senior Vice President, Preclinical Development & Protein Chemistry. Dr. Daly was previously Vice President, Preclinical Development & Protein Chemistry and before that held positions of increasing responsibility in Protein Sciences. Prior to Regeneron, Dr. Daly served as a research scientist at Repligen Corporation. Dr. Daly received his PhD in biochemistry from Rice University and his BS in biochemistry from Hofstra University.

  • Senior Vice President, Protein Expression Sciences

    James P. Fandl, PhD, joined Regeneron in 1989 as Scientist in the Protein Expression Group. During his tenure at Regeneron, Dr. Fandl has held numerous positions; he was appointed Vice President of Protein Expression Sciences in 2001 and Senior Vice President of Protein Expression Sciences in 2015. His research group developed the VelociMab® suite of proprietary technologies, including EESYR®, FASTR™, NICE® and BST, which enabled Dr. Fandl to demonstrate his knack for acronyms. He received his AB in Biology from Franklin & Marshall College and his PhD in Microbiology from the University of California, Davis.

  • Robert E. Landry

    Robert E. Landry

  • Joseph J. LaRosa

    Joseph J. LaRosa

  • Beth F. Levine

    Beth F. Levine

  • Senior Vice President, Finance and Chief Financial Officer

    Robert E. Landry joined the company in 2013 as Senior Vice President, Finance and Chief Financial Officer. Previously, Mr. Landry served as Senior Vice President and Treasurer of Pfizer Inc. Prior to this position, Mr. Landry held a variety of U.S. and international financial and general management positions at Wyeth Pharmaceuticals, Pfizer and PricewaterhouseCoopers LLP, including at Wyeth's Australian and New Zealand affiliates. He holds a BBA in Accounting from the University of Notre Dame.

  • Senior Vice President, General Counsel and Secretary

    Joseph J. LaRosa has been Senior Vice President, General Counsel and Secretary since September 2011. Previously, Mr. LaRosa held a number of senior legal positions at Schering-Plough Corporation, where he was a corporate officer and served most recently as Vice President, Legal Affairs, and as a member of the Operations Management Team. He also served as Vice President, Global Compliance and Legal Affairs at Avon Products, Inc. Most recently, Mr. LaRosa was Senior Vice President, General Counsel and Secretary at Nycomed U.S., Inc. Mr. LaRosa received his JD degree from New York University.

  • Senior Vice President, Associate General Counsel, Chief Compliance Officer

    Beth Levine joined Regeneron in 2008 and serves as Senior Vice President, Associate General Counsel and Chief Compliance Officer. Prior to joining Regeneron, Beth spent 13 years at Pfizer Inc., where she served in various positions in the Legal Division, culminating in the role of General Counsel - U.S. Pharmaceuticals, followed by 18 months at Keryx Biopharmaceuticals, Inc. as General Counsel and Chief Compliance Officer. In the early days of her legal career, Beth was a litigation associate at the law firm of Paul, Weiss, Rifkind, Wharton & Garrison, following a judicial clerkship with U.S. District Judge Gerard L. Goettel of the Southern District of New York. Beth received a BS from Cornell University and a JD from Fordham Law School.

  • Jay S. Markowitz, MD

    Jay S. Markowitz, MD

  • Andrew (Drew) Murphy

    Andrew (Drew) Murphy, PhD

  • Sally A. Paull

    Sally A. Paull

  • Senior Vice President, Portfolio Management

    Jay S. Markowitz, MD, joined Regeneron in 2017 as Senior Vice President, Portfolio Management. Dr. Markowitz was previously at Capital World Investors, where he was a U.S. pharmaceutical and biotechnology analyst and portfolio manager. Prior to Capital World Investors, Dr. Markowitz was a biotechnology analyst and portfolio manager at T. Rowe Price. Before transitioning to an investment career, he was an assistant professor and transplant surgeon at the Johns Hopkins University School of Medicine. Dr. Markowitz received his MD from Duke University and his BA from Columbia University.

  • Senior Vice President, Research, Regeneron Laboratories

    Drew Murphy, PhD, joined Regeneron in 1999 as Director of Genomics and Bioinformatics. He has led the Gene Discovery and Bioinformatics group and the Target Discovery group, and is now the Senior Vice President of Regeneron Laboratories. Dr. Murphy is a co-inventor of several of Regeneron's key technologies — VelociGene® and VelocImmune® — and continues to lead several Technology Centers and Therapeutic Focus Areas. Prior to joining Regeneron, Dr. Murphy worked for seven years at Cadus Pharmaceuticals. He received his BS in Molecular Biology at the University of Wisconsin, and his PhD in Human Genetics from Columbia University, College of Physicians and Surgeons.

  • Senior Vice President, Human Resources

    Sally A. Paull joined Regeneron as Senior Vice President, Human Resources in 2016. Ms. Paull was previously Executive Vice President, Chief Human Resources Officer at Inova Health System. Prior to Inova, she was Senior Vice President, Chief Human Resources Officer at Forest Laboratories. Earlier in her career, Ms. Paull served in progressively senior human resources roles at Dentsply International. She received her BA from the United States Air Force Academy and an MAIR from the University of Delaware.

  • Peter Powchik

    Peter Powchik, MD

  • Nicholas Papadopoulos

    Nicholas Papadopoulos, PhD

  • Neil Stahl

    Neil Stahl, PhD

  • Senior Vice President, Clinical Development

    Peter Powchik, MD, has been Senior Vice President, Clinical Development since October 2006. Prior to joining the company, Dr. Powchik served as Senior Vice President and Chief Medical Officer at Chugai Pharma USA, a position he held from May 2005 until October 2006. From April 2001 until May 2005, he held various senior clinical development positions at Novartis Pharmaceuticals Corporation, most recently as Vice President, U.S. Clinical Development and Medical Affairs. Dr. Powchik held various clinical development positions with Sepracor Inc. and Pfizer Inc. from October 1996 to April 2001. Dr. Powchik received his MD from New York University School of Medicine.

  • Senior Vice President, Research & Development Operations

    Nicholas Papadopoulos, PhD, joined Regeneron in 1996 as a Scientist in the Protein Sciences Department. In 2007, Dr. Papadopoulos was named Senior Director of Therapeutic Proteins, with responsibilities dedicated to overseeing the generation of fully human VelocImmune® antibodies. He was named Vice President in 2009 and Senior Vice President in January 2015. He received his BS in Chemistry from the State University of New York and his PhD in Chemistry from The Pennsylvania State University. Dr. Papadopoulos completed his postdoctoral training in the department of Microbiology and Immunology at the Albert Einstein College of Medicine.

  • Executive Vice President, Research and Development

    Neil Stahl, PhD, is Executive Vice President, Research and Development. Dr. Stahl started his career at Regeneron as a Staff Scientist in Discovery Research in 1991, working on cytokine receptor signaling. He spearheaded the invention and development of Regeneron's Trap Technology, which provided the basis of Regeneron's first three approved drugs. He also built the pre-clinical development team for the company and has overseen IND-enabling activities of over 19 therapeutic candidates. Dr. Stahl received his PhD in Biochemistry from Brandeis University, and then conducted post-doctoral research at the University of California, San Francisco before joining the company.

  • Robert J. Terifay

    Robert J. Terifay

  • Daniel Van Plew

    Daniel Van Plew

  • David Weinreich

    David Weinreich, MD, MBA

  • Executive Vice President, Commercial

    Robert J. Terifay is Executive Vice President, Commercial. Prior to joining Regeneron, Mr. Terifay served as President and Chief Operating Officer of Arginox Pharmaceuticals, Inc.; Senior Vice President, Business Operations at Synta Pharmaceuticals, Corp.; Senior Vice President, Oncology Commercial at Millennium Pharmaceuticals, Inc.; Vice President Marketing at COR Therapeutics, Inc.; Executive Vice President of Strategic Services at Saatchi & Saatchi and held various commercial and marketing positions at G.D. Searle & Company. Mr. Terifay received a Master of Management degree in Marketing and Health Service Management from the J.L. Kellogg Graduate School of Management, Northwestern University.

  • Executive Vice President and General Manager, Industrial Operations and Product Supply

    Daniel Van Plew has been Executive Vice President and General Manager, Industrial Operations and Product Supply since January 2016. He joined the company in July 2007, previously serving as Senior Vice President, Vice President and General Manager, Industrial Operations and Product Supply. Prior to his tenure at Regeneron, Mr. Van Plew served as Executive Vice President, R&D and Technical Operations of Crucell Holland B.V.; Senior Director, Vacaville Operations at Chiron Biopharmaceuticals, part of Chiron Corporation; and various managerial positions in the health and life sciences practice of Accenture, Ltd. Mr. Van Plew received an MSc in Chemistry from The Pennsylvania State University and an MBA from Michigan State University.

  • Senior Vice President, Global Clinical Development

    David Weinreich, MD, joined Regeneron as Senior Vice President, Late Stage Clinical Development and Medical Affairs in 2016.
    Dr. Weinreich was previously the Senior Vice President and Head of Global Development for Specialty Medicine at Bayer Pharmaceuticals. Prior to Bayer, Dr. Weinreich held positions of increasing responsibility focused on the development of oncology molecules at Amgen. Dr. Weinreich also previously served as Vice President of Clinical Affairs at Gene Logic and as an independent consultant, helping small to mid-stage biotechnology companies with drug commercialization. Dr. Weinreich received his MD from Boston University School of Medicine, his MBA from the McDonough School of Business at Georgetown University and his BS in computer engineering from Columbia University.

  • Leonard S. Schleifer

    Leonard S. Schleifer, MD, PhD

  • Founder, President and Chief Executive Officer

    Leonard S. Schleifer, MD, PhD, founded the company in 1988 while serving as an Assistant Professor of Neurology at Weill Cornell Medical College. Leveraging a lifelong passion for science and an entrepreneurial spirit, he has served as a Director and its President and Chief Executive Officer since its inception and acted as Chairman of the Board from 1990 through 1994. Dr. Schleifer received his MD and PhD in Pharmacology from the University of Virginia, and he is a licensed physician certified in neurology by the American Board of Psychiatry and Neurology.

  • George D. Yancopoulos

    George D. Yancopoulos, MD, PhD

  • President and Chief Scientific Officer

    George D. Yancopoulos, MD, PhD, is Regeneron’s President and Chief Scientific Officer. He has led Regeneron alongside Len Schleifer, MD, PhD, since 1989. George has been driven by science his entire life. He began his education at the Bronx High School of Science, received his MD and PhD from Columbia University and went on to become the 11th most highly cited scientist in the world in the 1990s. In 2004, he was elected to be a member of the National Academy of Sciences. Dr. Yancopoulos, together with key members of his team, is a principal inventor and developer of Regeneron's six FDA-approved drugs, as well as its foundational technologies, including the Trap technology, VelociGene® and VelocImmune®.

  • Ned Braunstein

    Ned Braunstein, MD

  • Senior Vice President, Regulatory Affairs & Pharmacovigilance

    Ned Braunstein, MD, joined Regeneron in 2009, and serves as Senior Vice President, Regulatory Affairs. Prior to Regeneron, he worked at Columbia University College of Physicians and Surgeons for 13 years as Assistant and then Associate Professor of Medicine and at Merck & Co., Inc, for nine years in positions of increasing responsibility in Clinical Research, Regulatory Affairs and Global Human Health. Dr. Braunstein received his BS in Medicine from Northwestern University in Evanston, Ill., and his MD from Northwestern University in Chicago.

  • Thomas Daly

    Thomas Daly, PhD

  • Senior Vice President, Preclinical Development & Protein Chemistry

    Thomas Daly, PhD, joined Regeneron in 1996. He is Senior Vice President, Preclinical Development & Protein Chemistry. Dr. Daly was previously Vice President, Preclinical Development & Protein Chemistry and before that held positions of increasing responsibility in Protein Sciences. Prior to Regeneron, Dr. Daly served as a research scientist at Repligen Corporation. Dr. Daly received his PhD in biochemistry from Rice University and his BS in biochemistry from Hofstra University.

  • James P. Fandl

    James P. Fandl, PhD

  • Senior Vice President, Protein Expression Sciences

    James P. Fandl, PhD, joined Regeneron in 1989 as Scientist in the Protein Expression Group. During his tenure at Regeneron, Dr. Fandl has held numerous positions; he was appointed Vice President of Protein Expression Sciences in 2001 and Senior Vice President of Protein Expression Sciences in 2015. His research group developed the VelociMab® suite of proprietary technologies, including EESYR®, FASTR™, NICE® and BST, which enabled Dr. Fandl to demonstrate his knack for acronyms. He received his AB in Biology from Franklin & Marshall College and his PhD in Microbiology from the University of California, Davis.

  • Robert E. Landry

    Robert E. Landry

  • Senior Vice President, Finance and Chief Financial Officer

    Robert E. Landry joined the company in 2013 as Senior Vice President, Finance and Chief Financial Officer. Previously, Mr. Landry served as Senior Vice President and Treasurer of Pfizer Inc. Prior to this position, Mr. Landry held a variety of U.S. and international financial and general management positions at Wyeth Pharmaceuticals, Pfizer and PricewaterhouseCoopers LLP, including at Wyeth's Australian and New Zealand affiliates. He holds a BBA in Accounting from the University of Notre Dame.

  • Joseph J. LaRosa

    Joseph J. LaRosa

  • Senior Vice President, General Counsel and Secretary

    Joseph J. LaRosa has been Senior Vice President, General Counsel and Secretary since September 2011. Previously, Mr. LaRosa held a number of senior legal positions at Schering-Plough Corporation, where he was a corporate officer and served most recently as Vice President, Legal Affairs, and as a member of the Operations Management Team. He also served as Vice President, Global Compliance and Legal Affairs at Avon Products, Inc. Most recently, Mr. LaRosa was Senior Vice President, General Counsel and Secretary at Nycomed U.S., Inc. Mr. LaRosa received his JD degree from New York University.

  • Beth F. Levine

    Beth F. Levine

  • Senior Vice President, Associate General Counsel, Chief Compliance Officer

    Beth Levine joined Regeneron in 2008 and serves as Senior Vice President, Associate General Counsel and Chief Compliance Officer. Prior to joining Regeneron, Beth spent 13 years at Pfizer Inc., where she served in various positions in the Legal Division, culminating in the role of General Counsel - U.S. Pharmaceuticals, followed by 18 months at Keryx Biopharmaceuticals, Inc. as General Counsel and Chief Compliance Officer. In the early days of her legal career, Beth was a litigation associate at the law firm of Paul, Weiss, Rifkind, Wharton & Garrison, following a judicial clerkship with U.S. District Judge Gerard L. Goettel of the Southern District of New York. Beth received a BS from Cornell University and a JD from Fordham Law School.

  • Jay S. Markowitz, MD

    Jay S. Markowitz, MD

  • Senior Vice President, Portfolio Management

    Jay S. Markowitz, MD, joined Regeneron in 2017 as Senior Vice President, Portfolio Management. Dr. Markowitz was previously at Capital World Investors, where he was a U.S. pharmaceutical and biotechnology analyst and portfolio manager. Prior to Capital World Investors, Dr. Markowitz was a biotechnology analyst and portfolio manager at T. Rowe Price. Before transitioning to an investment career, he was an assistant professor and transplant surgeon at the Johns Hopkins University School of Medicine. Dr. Markowitz received his MD from Duke University and his BA from Columbia University.

  • Andrew (Drew) Murphy

    Andrew (Drew) Murphy, PhD

  • Senior Vice President, Research, Regeneron Laboratories

    Drew Murphy, PhD, joined Regeneron in 1999 as Director of Genomics and Bioinformatics. He has led the Gene Discovery and Bioinformatics group and the Target Discovery group, and is now the Senior Vice President of Regeneron Laboratories. Dr. Murphy is a co-inventor of several of Regeneron's key technologies – VelociGene® and VelocImmune® – and continues to lead several Technology Centers and Therapeutic Focus Areas. Prior to joining Regeneron, Dr. Murphy worked for seven years at Cadus Pharmaceuticals. He received his BS in Molecular Biology at the University of Wisconsin, and his PhD in Human Genetics from Columbia University, College of Physicians and Surgeons.

  • Nicholas Papadopoulos

    Nicholas Papadopoulos, PhD

  • Senior Vice President, Research & Development Operations

    Nicholas Papadopoulos, PhD, joined Regeneron in 1996 as a Scientist in the Protein Sciences Department. In 2007, Dr. Papadopoulos was named Senior Director of Therapeutic Proteins, with responsibilities dedicated to overseeing the generation of fully human VelocImmune® antibodies. He was named Vice President in 2009 and Senior Vice President in January 2015. He received his BS in Chemistry from the State University of New York and his PhD in Chemistry from The Pennsylvania State University. Dr. Papadopoulos completed his postdoctoral training in the department of Microbiology and Immunology at the Albert Einstein College of Medicine.

  • Sally A. Paull

    Sally A. Paull

  • Senior Vice President, Human Resources

    Sally A. Paull joined Regeneron as Senior Vice President, Human Resources in 2016. Ms. Paull was previously Executive Vice President, Chief Human Resources Officer at Inova Health System. Prior to Inova, she was Senior Vice President, Chief Human Resources Officer at Forest Laboratories. Earlier in her career, Ms. Paull served in progressively senior human resources roles at Dentsply International. She received her BA from the United States Air Force Academy and an MAIR from the University of Delaware.

  • Peter Powchik

    Peter Powchik, MD

  • Senior Vice President, Clinical Development

    Peter Powchik, MD, has been Senior Vice President, Clinical Development since October 2006. Prior to joining the company, Dr. Powchik served as Senior Vice President and Chief Medical Officer at Chugai Pharma USA, a position he held from May 2005 until October 2006. From April 2001 until May 2005, he held various senior clinical development positions at Novartis Pharmaceuticals Corporation, most recently as Vice President, U.S. Clinical Development and Medical Affairs. Dr. Powchik held various clinical development positions with Sepracor Inc. and Pfizer Inc. from October 1996 to April 2001. Dr. Powchik received his MD from New York University School of Medicine.

  • Neil Stahl

    Neil Stahl, PhD

  • Executive Vice President, Research and Development

    Neil Stahl, PhD, is Executive Vice President, Research and Development. Dr. Stahl started his career at Regeneron as a Staff Scientist in Discovery Research in 1991, working on cytokine receptor signaling. He spearheaded the invention and development of Regeneron's Trap Technology, which provided the basis of Regeneron's first three approved drugs. He also built the pre-clinical development team for the company and has overseen IND-enabling activities of over 19 therapeutic candidates. Dr. Stahl received his PhD in Biochemistry from Brandeis University, and then conducted post-doctoral research at the University of California, San Francisco before joining the company.

  • Robert J. Terifay

    Robert J. Terifay

  • Executive Vice President, Commercial

    Robert J. Terifay is Executive Vice President, Commercial. Prior to joining Regeneron, Mr. Terifay served as President and Chief Operating Officer of Arginox Pharmaceuticals, Inc.; Senior Vice President, Business Operations at Synta Pharmaceuticals, Corp.; Senior Vice President, Oncology Commercial at Millennium Pharmaceuticals, Inc.; Vice President Marketing at COR Therapeutics, Inc.; Executive Vice President of Strategic Services at Saatchi & Saatchi and held various commercial and marketing positions at G.D. Searle & Company. Mr. Terifay received a Master of Management degree in Marketing and Health Service Management from the J.L. Kellogg Graduate School of Management, Northwestern University.

  • Daniel Van Plew

    Daniel Van Plew

  • Executive Vice President and General Manager, Industrial Operations and Product Supply

    Daniel Van Plew has been Executive Vice President and General Manager, Industrial Operations and Product Supply since January 2016. He joined the company in July 2007, previously serving as Senior Vice President, Vice President and General Manager, Industrial Operations and Product Supply. Prior to his tenure at Regeneron, Mr. Van Plew served as Executive Vice President, R&D and Technical Operations of Crucell Holland B.V.; Senior Director, Vacaville Operations at Chiron Biopharmaceuticals, part of Chiron Corporation; and various managerial positions in the health and life sciences practice of Accenture, Ltd. Mr. Van Plew received an MSc in Chemistry from The Pennsylvania State University and an MBA from Michigan State University.

  • David Weinreich

    David Weinreich, MD, MBA

  • Senior Vice President, Global Clinical Development

    David Weinreich, MD, joined Regeneron as Senior Vice President, Late Stage Clinical Development and Medical Affairs in 2016. Dr. Weinreich was previously the Senior Vice President and Head of Global Development for Specialty Medicine at Bayer Pharmaceuticals. Prior to Bayer, Dr. Weinreich held positions of increasing responsibility focused on the development of oncology molecules at Amgen. Dr. Weinreich also previously served as Vice President of Clinical Affairs at Gene Logic and as an independent consultant, helping small to mid-stage biotechnology companies with drug commercialization. Dr. Weinreich received his MD from Boston University School of Medicine, his MBA from the McDonough School of Business at Georgetown University and his BS in computer engineering from Columbia University.